Oslo, November 21st 2024: Lytix Biopharma refers to the release made today by its licensing partner Verrica Pharmaceuticals, announcing the pricing of a USD 42 million underwritten public offering. The offering is expected to close on November 22, 2024, and the gross proceeds from the offering are expected to be …
